HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to keep High-Risk breast cancer at bay
Disease control Recruiting nowThis study tests if a new hormone therapy called elacestrant can better prevent breast cancer from coming back in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant or standard hormone therapy for up to 7.5 years. The goa…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New pill aims to shrink advanced tumors in first human trial
Disease control Recruiting nowThis study tests a new oral drug, AVZO-023, for people with advanced solid tumors, including a type of breast cancer (HR+/HER2-). The goal is to find the safest dose and see if it can shrink tumors. About 380 adults will take the drug alone or with other treatments.
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study is for people with a type of advanced breast cancer called HR+/HER2-. It tests two experimental drugs, sapanisertib and serabelisib, given with standard hormone therapy. The goal is to see if the combination is safe and can shrink tumors. About 32 participants will tak…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new oral drug, NKT5097, in 205 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. The study focuses on breast cancer and other tumors with specific g…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate more cancer cells in women with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then undergo surgery. After…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New study tracks Real-World impact of targeted cancer drugs in advanced breast cancer
Knowledge-focused Recruiting nowThis study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these treatments control the cancer in real-world settings. The goal is to gather information…
Matched conditions: HR+/HER2- BREAST CANCER
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC